StreetInsider.com News Articles

JPMorgan Starts Hemab Therapeutics Holdings (COAG) at Overweight

Thu, 15 Oct 2026 02:55:18 -0400

JPMorgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Overweight rating and a price target of $70.00.

The analyst comments: “Hemab has an emerging pipeline of early to mid-late stage assets all designed to address the need for subcutaneous prophylactic (preventive) therapies to treat underserved bleeding disorders. Lead asset sutacimig (FVIIa x TLT-1 bispecific) has generated compelling phase 1/2 data in Glanzmann thrombasthenia (GT) and is expected to enter phase 3 in 2H26. In parallel, a phase 2b POC study of sutacimig is ongoing in Factor VII deficiency (FVIID), with interim data expected in late 2026/early

JPMorgan Starts Hemab Therapeutics Holdings (COAG) at Overweight

Thu, 15 Oct 2026 02:55:18 -0400

JPMorgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Overweight rating and a price target of $70.00.

Rodman & Renshaw Starts Hemab Therapeutics Holdings (COAG) at Buy

Mon, 12 Oct 2026 07:31:03 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $56.00.

The analyst comments "We are initiating coverage of Hemab Therapeutics with a BUY rating and $56 price target based on sutacimig's path to becoming the first approved prophylactic therapy in Glanzmann thrombasthenia, backed by a second engine in Von Willebrand disease. Hemab has spent nearly a decade on coagulation disorders that larger hematology franchises left behind, where decades-old plasma products and short-acting bypassing agents have never given way to a subcutaneous, prophylactic option."

For an analyst ratings

Rodman & Renshaw Starts Hemab Therapeutics Holdings (COAG) at Buy

Mon, 12 Oct 2026 07:31:03 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $56.00.

For an analyst ratings

Form 4 Hemab Therapeutics Holdi For: Sep 24 Filed by: Walbert Keli

Fri, 25 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260925/27107995.html

Form 3 Hemab Therapeutics Holdi For: Sep 24 Filed by: Walbert Keli

Fri, 25 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260925/27107788.html

Form 8-K Hemab Therapeutics Holdi For: Sep 24

Thu, 24 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260924/27102160.html

Hemab Therapeutics adds Keli Walbert to its board of directors

Thu, 24 Sep 2026 16:01:31 -0400

Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company focused on blood coagulation disorders, announced the appointment of Keli Walbert to its board of directors, effective Sept. 24, 2026.

Walbert will join the board's Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a board member.

Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals, including roles spanning sales and marketing, market access, patient services, and analytics. She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy across more than 10 marketed brands.

Earlier in her career, she held leadership roles at

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

Thu, 24 Sep 2026 16:01:00 -0400

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbert will join the Board’s Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a member of the Board.

“Keli's experience turning novel scientific innovations into therapies

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

Thu, 24 Sep 2026 16:01:00 -0400

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

“Keli's experience turning novel scientific innovations into therapies

Hemab doses first participant in Phase 1 trial for HMB-003

Thu, 17 Sep 2026 08:00:18 -0400

Hemab Therapeutics (Nasdaq: COAG) announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating HMB-003, an investigational therapy for heavy menstrual bleeding.

HMB-003 is a subcutaneously administered, fatty-acid-conjugated peptide antifibrinolytic designed to stabilize clots and reduce bleeding by directly inhibiting plasmin at its active site. In preclinical studies conducted in minipigs, a single subcutaneous dose achieved peak plasma levels within hours and maintained antifibrinolytic activity for approximately one week.

The Phase 1 study (NCT07798505) is a randomized, placebo-controlled, single-ascending-dose escalation trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMB-003 in healthy adult volunteers. Results are

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Thu, 17 Sep 2026 08:00:00 -0400

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare professional in the U.S. last year.

It is the leading cause of iron deficiency and anemia among premenopausal women, and the primary symptom driving hysterectomies in the U.S.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience,

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Thu, 17 Sep 2026 08:00:00 -0400

It is the leading cause of iron deficiency and anemia among premenopausal women, and the primary symptom driving hysterectomies in the U.S.

Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Novo Holdings A/S

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932620.html

Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Avoro Capital Advisors LLC

Fri, 14 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26925554.html

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and &q